

Financial news for IMNP dated on 2018-07-27: Stocks Which Set New 52-Week Low Yesterday, July 26th:

Financial news for IMNP dated on 2018-07-26: Stocks Which Set New 52-Week Low Yesterday, July 25th

Financial news for IMNP dated on 2018-07-26: Immune Pharma Reports Received Nasdaq Delisting Determination, Says Is Eligible To Trade OTC Starting Jul. 26, 2018

Financial news for IMNP dated on 2018-07-26: Benzinga's Daily Biotech Pulse: Biogen, AC Immune Slip Despite Positive Trials, Sarepta Slapped With Clinical Hold

Financial news for IMNP dated on 2018-07-17: Immune Pharma Reports Filing Of Proxy Statement For Stock Split Between 1-For-5, 1-For-20 Stock Split

Financial news for IMNP dated on 2018-07-09: Immune Pharmaceuticals Shares Up After Co. Announced Antibody Development And Manufacturing Partnership With WuXi Biologics

Financial news for IMNP dated on 2018-07-09: WuXi Biologics, Immune Pharmaceuticals Report Late-phase Development and Manufacturing Partnership for a First-In-Class Monoclonal Antibody

Financial news for IMNP dated on 2018-06-22: Benzinga's Daily Biotech Pulse: FDA Greenlights Tandem Diabetes' Insulin Pump, More IPOs On Tap

Financial news for IMNP dated on 2018-06-08: Immune Pharma Says Is Initiating Search For Non-Exec. Chair, Added Board Members

Financial news for IMNP dated on 2018-06-08: UPDATE: Immune Pharma Says Co. Plans To Timely Request A Hearing Before Nasdaq Listing Qualifications Panel, Which Will Stay Suspension, Any Delisting Action At Least Pending Issuance Of Panel Decision

Financial news for IMNP dated on 2018-06-08: Immune Pharma Reports Received Letter From Listing Qualifications Dept. Of Nasdaq Related To Co.'s Failure To Regain Compliance With Minimum \$1/Share Bid Price Requirement

Financial news for IMNP dated on 2018-05-23: Immune Pharmaceuticals Shares Up 6%; Note: Shares Closed Down 5% On Pipeline Update, COO Increased Stake From 50K Shares To 75K Shares

Financial news for IMNP dated on 2018-05-23: Immune Pharma Offers Update On Pipeline: Bertilimumab, NanoCyclo, Discusses Near-Term Milestones

Financial news for IMNP dated on 2018-05-22: Benzinga's Daily Biotech Pulse: Melinta, Ardelyx Pull Back On Offerings, Insys Awaits FDA Verdict

Financial news for IMNP dated on 2018-05-16: Benzinga's Daily Biotech Pulse: Verastem Uprooted On Stock Offering, Titan Pharma Earnings

Financial news for IMNP dated on 2018-05-15: UPDATE: Immune Pharma Says Data On Bertilimumab Supports Co.'s Plans To Begin Pivotal Registration Study In '19

Financial news for IMNP dated on 2018-05-15: Immune Pharma Offers Updated Results From Phase 2 Trial Of Bertilimumab In Bullous Pemphigoid: 'Results from all subjects confirm excellent safety and tolerability and a large benefit across a variety of efficacy measures...'

Financial news for IMNP dated on 2018-05-07: UPDATE: Immune Pharma Mgmt. Has Initiated Discussions With Parties Potentially Interested In Buying Certain Cytovia Assets

Financial news for IMNP dated on 2018-05-07: Immune Pharma Reports Board Says Will No Longer Pursue Spin Off Of Oncology-Focused Subsidiary, Cytovia

Financial news for IMNP dated on 2018-04-02: Immune Pharma FY17 EPS \$(2.11) vs \$(9.58) In FY16

Financial news for IMNP dated on 2018-02-20: Immune Pharmaceuticals Shares Down 13.1%; Earlier Co. Announced Failure To Ratify Vote Approving Proposed Reverse Stock Split, Will Reconvene Feb. 23rd

Financial news for IMNP dated on 2018-02-08: 19 Biotech Stocks With Clinical Trial Outcomes In February

Financial news for IMNP dated on 2018-01-05: Maxim Group Initiates Coverage On Immune Pharmaceuticals with Buy Rating, Announces \$3.00 Price Target

Financial news for IMNP dated on 2017-11-15: Immune Pharma Reports Cash Of \$76K as Of Sept. 30, 2017, R&D Expenses Fell By \$1.1M To \$1.2M During Q3

Financial news for IMNP dated on 2017-10-20: 38 Biggest Movers From Yesterday

Financial news for IMNP dated on 2017-10-19: Mid-Afternoon Market Update: Crude Oil Down 1.25%; Alcobra Shares Spike Higher

Financial news for IMNP dated on 2017-10-19: 32 Stocks Moving In Thursday's Mid-Day Session

Financial news for IMNP dated on 2017-10-19: Mid-Day Market Update: Heritage-Crystal Clean Drops On Weak Q3 Results; Imprimis Pharmaceuticals Shares Surge

Financial news for IMNP dated on 2017-10-19: Immune Pharmaceuticals Shares Down 39.21%; Earlier Co. Announced Pricing Of \$18M Mixed Offering

Financial news for IMNP dated on 2017-10-19: Mid-Morning Market Update: Markets Open Lower; Verizon Sales Beat Estimates

Financial news for IMNP dated on 2017-09-27: Immune Pharmaceuticals Announces 'Positive' Results from Ongoing Phase 2 Trial of Bertilimumab in Bullous Pemphigoid

Financial news for IMNP dated on 2017-08-24: 12 Biggest Mid-Day Losers For Thursday

Financial news for IMNP dated on 2017-08-24: Mid-Morning Market Update: Markets Edge Lower; Dollar Tree Profit Tops Expectations

Financial news for IMNP dated on 2017-08-24: 25 Stocks Moving In Thursday's Pre-Market Session

Financial news for IMNP dated on 2017-08-14: Immune Pharmaceuticals Names Dr. Tony Fiorino Chief Medical Officer, COO

Financial news for IMNP dated on 2017-08-07: Immune Pharma Subsidiary Cytovia Announces Publication Of New Results, Filing Of World-Wide Patent Protecting CEPLENE

Financial news for IMNP dated on 2017-08-04: Immune Pharma Issues Release Disclosing Letter To Holders

Financial news for IMNP dated on 2017-07-19: UPDATE: Immune Pharma Says Holders Will Received Added Pro-Rata Shares In Cytovia

Financial news for IMNP dated on 2017-07-19: Immune Pharma Offers Update On Plan To Implement Spin-Off Of Cytovia Into Separate Publicly-Traded Co.

Financial news for IMNP dated on 2017-07-14: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for IMNP dated on 2017-07-13: IMMUNE Pharma Files for Patent to Protect the Use of Ceplene

Financial news for IMNP dated on 2017-07-11: Immune Pharma Reports Unit Cytovia Enters Deal With Pint For Licensing, Commercialization Of Ceplene In Latin America

Financial news for IMNP dated on 2017-07-05: UPDATE: IMMUNE Pharma Reports 67% Of Patients With Functional NK Cells Remained Disease Free At Pre-Determined End Point Which Followed 2 Years Of Treatment

Financial news for IMNP dated on 2017-07-05: Immune Pharmaceuticals Reports Additional Clinical Results On Ceplene Efficacy For Patients With AML Were Recently Published In Leukemia, A Leading Hematology Journal

Financial news for IMNP dated on 2017-06-29: Immune Pharma Reports Cytovia Oncology Unit Reached Deal On Material Terms Of Licensing, Commercialization Deal Of Ceplene In Latin America With Pint Pharma

Financial news for IMNP dated on 2017-06-28: 13G Filing From Brian Skidmore On Immune Pharma Shows 4.1% Stake

Financial news for IMNP dated on 2017-06-21: 20 Stocks Moving In Wednesday's Pre-Market Session

Financial news for IMNP dated on 2017-06-20: Immune Pharma Reports Initiation Of Enrollment In Trial With Ceplene / Low-Dose IL-2 In Chronic Myelomonocytic Leukemia

Financial news for IMNP dated on 2017-06-19: Immune Announces They Have Regained NASDAQ Listing Compliance

Financial news for IMNP dated on 2017-06-15: Immune Pharmaceuticals Signs Agreement to Regain Worldwide Rights for Ceplene, Terms Not Disclosed

Financial news for IMNP dated on 2017-05-26: 22 Stocks Moving In Friday's Pre-Market Session

Financial news for IMNP dated on 2017-05-16: Immune Pharma Files Non-Timely 10-Q

Financial news for IMNP dated on 2017-05-04: Immune Pharmaceuticals Reports Private Placement of up to \$3.4 Million

Financial news for IMNP dated on 2017-04-26: 25 Stocks Moving In Wednesday's Pre-Market Session

Financial news for IMNP dated on 2017-04-24: Immune Pharma Reports Corporate Restructuring

Financial news for IMNP dated on 2017-04-24: Immune Pharma Reports Received Written Notice from Listing Qualifications Department at NASDAQ of Noncompliance Related to Filing of 10-K

Financial news for IMNP dated on 2017-04-21: 15 Biggest Mid-Day Losers For Friday

Financial news for IMNP dated on 2017-04-21: 25 Stocks Moving In Friday's Pre-Market Session

Financial news for IMNP dated on 2017-04-20: Mid-Afternoon Market Update: Dow Surges 200 Points; RLI Shares Drop On Disappointing Results

Financial news for IMNP dated on 2017-04-20: 15 Biggest Mid-Day Gainers For Thursday

Financial news for IMNP dated on 2017-04-20: Mid-Day Market Update: Select Comfort Rises On Upbeat Earnings; Texas Capital Bancshares Shares Slide

Financial news for IMNP dated on 2017-04-20: Mid-Morning Market Update: Markets Edge Higher; Verizon Profit Misses Expectations

Financial news for IMNP dated on 2017-04-20: Immune Pharma Reports Signing of Letter of Intent with Pint Pharma for License, Commercialization of Ceplene in Latin America

Financial news for IMNP dated on 2017-04-17: 15 Biggest Mid-Day Losers For Monday

Financial news for IMNP dated on 2017-04-17: 20 Stocks Moving In Monday's Pre-Market Session

Financial news for IMNP dated on 2017-04-12: Immune Pharmaceuticals Reports 1-for-20 Reverse Stock Split

Financial news for IMNP dated on 2017-03-23: Immune Pharmaceuticals Entered into Common Stock Purchase Agreement with HLHW IV, LLC to Buy Up to \$1.6M of Co's Common Stock

Financial news for IMNP dated on 2017-02-28: Immune Pharmaceuticals Submits Orphan Drug Designation For Bertilimumab in BP

Financial news for IMNP dated on 2017-01-27: Immune Pharma Names Ranch Kimball Chair

Financial news for IMNP dated on 2017-01-23: Immune Pharma Reports Research Partnership to Develop Mono-, Bispecific Antibodies Against Novel Targets in Tumor Microenvironment

Financial news for IMNP dated on 2016-12-12: Synergy Pharma's Chief Strategist Discusses Recent Results And Coming Catalysts

Financial news for IMNP dated on 2016-12-12: Immune Pharmaceuticals CEO Talks Company And Its Recent Market Rally

Financial news for IMNP dated on 2016-11-29: Martin Shkreli Tweets: \$NVS slightly undervalued, no surprise--market is good at arbitraging large cos. Moving to penny stock trash \$IMNP. hitbox.tv/martinshkrelilil...

Financial news for IMNP dated on 2016-11-22: Immune Pharmaceuticals Announces Immuno-Oncology R&D Update on December 8, 2016; Confirms Pivotal Phase 3 Overall Survival Study With Ceplene In AML

Financial news for IMNP dated on 2016-11-22: Immune Pharmaceuticals Entered into Securities Purchase Agreement with HLHW IV, LLC

Financial news for IMNP dated on 2016-10-27: Immune Pharmaceuticals Receives FDA Guidance for Low Dose IL-2 in Combination with Phase III Pivotal Trial of its AML Therapy Ceplene

Financial news for IMNP dated on 2016-09-16: Immune Pharma Entered Binding Deal with NPT to Buy Up to \$20M of Capital Stock of Maxim

Financial news for IMNP dated on 2016-09-16: Immune Pharma Reports Deal to Fund Maxim Pharma

Financial news for IMNP dated on 2016-09-07: Immune Pharmaceuticals Receives \$2 Million Investment in Common Stock at \$0.50 per Share

Financial news for IMNP dated on 2016-08-16: Immune Pharmaceuticals Reports Q2 EPS \$(0.13) vs. Est. \$(0.13)

Financial news for IMNP dated on 2016-07-19: IMMUNE Pharmaceuticals to Form Pain and Neurology Spin Off Company around AmiKet

Financial news for IMNP dated on 2016-06-28: Immune Pharma Says Data Suggests Improved Tumor Response For The Combination of AZIXA and Immune Checkpoint Inhibitors in The Treatment of Cancer

Financial news for IMNP dated on 2016-06-14: Immune Pharmaceuticals Expands its Bertilimumab Phase II Clinical Trial in Bullous Pemphigoid to Six Academic Institutions in the United States

Financial news for IMNP dated on 2016-06-07: Immune Pharmaceuticals, Hadasit File Joint Patent on Oral Use of Anti-Eotaxin Monoclonal Antibodies, Including Bertilimumab

Financial news for IMNP dated on 2016-05-16: Immune Pharma Q1 EPS (\$0.17) vs (\$0.15) est

Financial news for IMNP dated on 2016-04-20: Immune Pharmaceuticals Announces Regatta Select Healthcare to Purchase up to 3.5M Shares of the Company's Common Stock -8K

Financial news for IMNP dated on 2016-03-30: Immune Pharma Reports Q4 EPS \$(0.27) vs \$(0.14) Est.

Financial news for IMNP dated on 2016-03-22: Immune Pharmaceuticals Announces Publication of Preclinical Data in Support of Its Bispecific Antibody Platform in The Journal of Immunology

Financial news for IMNP dated on 2016-02-24: Immune Pharmaceuticals Reports Publication of New Data on Eotaxin-1 in IBD; Patient Enrollment in Phase II UC Trial Continues

Financial news for IMNP dated on 2016-01-04: Immune Pharmaceuticals Reports New Data with Topical Cyclosporine Nano-Capsules in Dermatology, Alert hits:All Company Symbols: NASDAQ-SMALL:IMNP Immune Acquires Worldwide Rights and Accelerates Development for the Treatment of Psoriasis

Financial news for IMNP dated on 2015-12-28: Immune Pharmaceuticals Announces Exclusive License to a Novel Bispecific Antibody Technology

Financial news for IMNP dated on 2015-12-14: Immune Pharmaceuticals Reports New Data with Bi-Specific Antibody, Immune Described Postivie Developements With Novel Platform For Production Of tetravalent IgG1-like bi-specific Antibodies In Study

Financial news for IMNP dated on 2015-11-17: Immune Pharma Reports Enrollment of First Patient in Phase 2 Trial with Bertilimumab in UC

Financial news for IMNP dated on 2015-11-17: Immune Pharmaceuticals Reports Enrollment of the Initial Patient into the Phase 2 Clinical Trial with Bertilimumab in Ulcerative Colitis

Financial news for IMNP dated on 2015-11-12: Immune Pharma Reports Q3 EPS \$(0.35) vs \$(0.18) Est.

Financial news for IMNP dated on 2015-11-09: Immune Pharma Reports FDA Acceptance of IND App for Bertilimumab

Financial news for IMNP dated on 2015-10-07: Immune Pharmaceuticals Submits Investigational New Drug Application in the U.S. for its Lead Product Candidate Bertilimumab for the Treatment of Bullous Pemphigoid

Financial news for IMNP dated on 2015-10-02: Morning Market Losers

Financial news for IMNP dated on 2015-08-26: S-3 Filing Shows Immune Pharmaceuticals Offering \$14M Mixed Shelf Offering

Financial news for IMNP dated on 2015-08-17: Immune Pharma Q2 EPS -\$0.12 vs -\$0.22 est

Financial news for IMNP dated on 2015-07-08: Immune Pharmaceuticals Amends Pain Licensing Agreement With Endo Pharmaceuticals

Financial news for IMNP dated on 2015-06-29: Immune Pharmaceuticals Signs License & Research Agreement for AmiKet Nano

Financial news for IMNP dated on 2015-06-25: Immune Pharmaceuticals Begins Phase II Clinical Trials With Bertilimumab In Ulcerative Colitis, Bullous Pemphigoid

Financial news for IMNP dated on 2015-06-10: Immune Pharmaceuticals Expands Immuno-Dermatology Development Portfolio With Topical Nano-Formulated Cyclosporine A

Financial news for IMNP dated on 2015-05-27: Immune Pharmaceuticals To Showcase at Sachs Immuno-Oncology Business Development and Investment Forum in Chicago and at Marcum Conference in New York

Financial news for IMNP dated on 2015-05-04: Immune Pharmaceuticals And STC Biologics Announce Strategic Partnership To Accelerate The Development of NanomAbs

Financial news for IMNP dated on 2015-03-31: Immune Pharmaceuticals To Expand Bullous Pemphigoid Clinical Development Plan For Bertilimumab

Financial news for IMNP dated on 2015-03-09: Chardan Capital Initiates Coverage on Immune Pharmaceuticals at Buy, Announces \$5.50 PT

Financial news for IMNP dated on 2015-01-21: Immune Pharmaceuticals Appoints Gad Berdugo As CFO; Cameron Durrant as Lead Independent Director

Financial news for IMNP dated on 2014-11-20: Immune Pharmaceuticals Inc. Announces Pricing Of Public Offering Of Common Stock

Financial news for IMNP dated on 2014-10-22: Immune Pharmaceuticals Announces New Clinical Data Supports Development of Bertilimumab in Both Ulcerative Colitis and Crohn's Disease

Financial news for IMNP dated on 2014-09-08: S-3 from Immune Pharma Shows Registration for \$750M Mixed Securities Shelf Offering